TARA PEMBERTON: Open Payments
NPI 1275803462 · PORTLAND, OR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$919 in 44 payments from 11 companies in 2025. Trend: 2023 $491 · 2024 $376 · 2025 $919
Food & beverage: $919
| Company | Payments | Amount |
|---|---|---|
| CSL Behring | 17 | $300 |
| GENZYME CORPORATION | 11 | $232 |
| Regeneron Healthcare Solutions, Inc. | 3 | $94 |
| Genentech USA, Inc. | 3 | $67 |
| Novartis Pharmaceuticals Corporation | 4 | $63 |
| Ionis Pharmaceuticals, Inc. | 1 | $38 |
| BioCryst US Sales Co., LLC | 1 | $33 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $28 |
| Incyte Corporation | 1 | $26 |
| AstraZeneca Pharmaceuticals LP | 1 | $21 |
Products named: DUPIXENT, Hizentra, Andembry, Xolair, Rhapsido, DAWNZERA, ORLADEYO, TAKHZYRO.
Industry payments across OR — which companies pay providers there.
